




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof



Better Late than Never: Eventual Seroconversion against SARS-CoV-2 in a Kidney Transplant Recipient after Repeated Immune Challenge and Monoclonal Antibody Therapy.

Julien De Greef, MD, Arnaud Devresse, PhD, Imane Saad Albichr, PharmD, Anais Scohy, PharmD, Nada Kanaan, MD, H  l  ne Georgery, MD, Leila Belkhir, PhD, Benoit Kabamba, PhD, Jean Cyr Yombi, MD, Eric Goffin, MD

PII: S0085-2538(21)00825-5

DOI: <https://doi.org/10.1016/j.kint.2021.08.018>

Reference: KINT 2750

To appear in: *Kidney International*

Received Date: 12 July 2021

Revised Date: 24 August 2021

Accepted Date: 26 August 2021

Please cite this article as: De Greef J, Devresse A, Albichr IS, Scohy A, Kanaan N, Georgery H, Belkhir L, Kabamba B, Yombi JC, Goffin E, Better Late than Never: Eventual Seroconversion against SARS-CoV-2 in a Kidney Transplant Recipient after Repeated Immune Challenge and Monoclonal Antibody Therapy., *Kidney International* (2021), doi: <https://doi.org/10.1016/j.kint.2021.08.018>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright    2021, Published by Elsevier, Inc., on behalf of the International Society of Nephrology.

**Better Late than Never: Eventual Seroconversion against SARS-CoV-2 in a Kidney
Transplant Recipient after Repeated Immune Challenge and Monoclonal Antibody
Therapy.**

Julien De Greef, MD ^{1*}, Arnaud Devresse, PhD^{2*}, Imane Saad Albichr, PharmD³, Anais Scohy,
PharmD³, Nada Kanaan, MD², Hélène Georgery, MD², Leila Belkhir, PhD¹, Benoit Kabamba,
PhD³, Jean Cyr Yombi, MD¹, Eric Goffin, MD²

Affiliations:

Department of Internal Medicine and Infectious Disease¹, Nephrology², Microbiology³, Saint-
Luc University Clinics, Brussels, Belgium

*These authors participated equally to this work

Corresponding author:
Arnaud Devresse, MD, PhD
Department of Nephrology
Cliniques Universitaires Saint-Luc
arnaud.devresse@uclouvain.be

Keywords: SARS-CoV-2, Monoclonal Antibody

Funding: none

Disclosures: none

Kidney transplant recipients (KTRs) are disproportionately affected by COVID-19. In addition to limited therapeutic options, concerns have arisen regarding poor vaccine efficacy in this population.¹

We report the case of a 64-year-old KTR treated with an association of tacrolimus, mycophenolate mofetil (MMF) and steroids who developed a second SARS-CoV-2 infection one year after a first COVID-19 episode, and 55 days after receiving his second BNT162b2-mRNA vaccine injection. Three days after the onset of isolated fever, high viral load of SARS-CoV-2 gamma variant was detected through RT-PCR in a nasopharyngeal swab (Table 1). MMF was interrupted and intravenous monoclonal antibodies (casirivimab 1200mg and imdevimab 1200mg, Regeneron, USA) therapy was given. Clinical and virological evolutions were favorable: viral load decreased <1000 copies/mL on day 8 and was eventually negative on day 28 after perfusion (Table 1). Interestingly, an anti-N native antibody seroconversion was observed on day 28 (Table 1). Notably, three serologic tests had been performed before the second SARS-CoV-2 infection (including one 43 days after the second vaccine dose injection) and were all negative for both anti-N and anti-RBD antibody.

Anti-SARS-CoV-2 monoclonal antibodies have shown promising effects in COVID-19², and preliminary results suggest efficacy in preventing severe disease after solid organ transplantation.³ Our patient eventually mounted a natural immunity against SARS-CoV-2 in a context of repeated previous immune challenges and immunosuppression tapering. The effect of passive immunization on the development of protective immunity remains unknown.⁴ Whether monoclonal antibodies infusion has promoted the development of natural immunity against SARS-CoV-2 remains to be investigated.

References

- (1) Georgery H, Devresse A, Yombi JC, et al. Disappointing Immunization Rate after two Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients. Transplantation [Published online June 24, 2021]
- (2) Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients. medRxiv 2021.05.19.21257469; doi: <https://doi.org/10.1101/2021.05.19.21257469>
- (3) Del Bello A, Marion O, Vellas C, Faguer S, Izopet S, Kamar N. Anti-SARS-Cov-2 Monoclonal Antibodies in Solid-Organ-Transplant Patients. Transplantation [Published online June 30, 2021]
- (4) Taylor PC, Adams AC, Hufford MH, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21: 382-393.

Table 1: Evolution of SARS-CoV-2 viral load and anti-SARS-CoV-2 antibody titers after monoclonal antibodies therapy

	Day 0	Day 8	Day 28
Viral load (copies/mL)	10 264 225	570	0
Anti-N antibody (index)	0.083	0.221	7.74
Anti-RBD antibody titer (U/mL)	0.701	57 753	40 135

Day 0= day of monoclonal antibodies perfusion.

Positivity thresholds: anti-N antibody ≥ 1 , anti-RBD antibody ≥ 0.8 U/mL (upper detection limit of the assay: 250 U/mL).